Amedeo Smart

Free Medical Literature Service

 

Amedeo

Contraception and Contraceptive Drugs
  Free Subscription

Articles published in
Gynecol Endocrinol
    December 2024
  1. COSAR A, Ozcan P, Tanoglu FB, Tok OE, et al
    Comparative effects of the antioxidant glutathione with metformin and Diane-35 on hormonal, metabolic, and inflammatory indicators in a DHEA-induced PCOS rat model.
    Gynecol Endocrinol. 2024;40:2302086.
    >> Share

  2. HAN SJ, Kim H, Ku SY, Suh CS, et al
    Comparison of resumption of ovulation after cessation of oral contraceptives and medroxyprogesterone acetate in women with polycystic ovary syndrome.
    Gynecol Endocrinol. 2024;40:2309349.
    >> Share

  3. LA TORRE F, Vannuccini S, Toscano F, Gallucci E, et al
    Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability.
    Gynecol Endocrinol. 2024;40:2336121.
    >> Share

    December 2023
  4. FARRIS M, Arisi E, Mirjalili N, Nappi RE, et al
    Attitudes of women and pharmacists on the opportunity to obtain a progestogen-only pill over the counter - Italian outcomes.
    Gynecol Endocrinol. 2023;39:2206922.
    >> Share

  5. GENAZZANI AR, Fidecicchi T, Arduini D, Giannini A, et al
    Hormonal and natural contraceptives: a review on efficacy and risks of different methods for an informed choice.
    Gynecol Endocrinol. 2023;39:2247093.
    >> Share

  6. NAPPI RE, Farris M, Gallina Toschi A, Michieli R, et al
    Overcoming barriers to oral contraception in Italy an expert opinion to empower women.
    Gynecol Endocrinol. 2023;39:2254400.
    >> Share

  7. PALACIOS S, Ayala G, Gonzalez G, Badilla-Apuy CL, et al
    Combined oral contraceptives: update recommendations of the Latin American contraceptive association.
    Gynecol Endocrinol. 2023;39:2271072.
    >> Share

  8. QI Q, Xia Y, Luo J, Wang Y, et al
    Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for the prevention of ovarian hyperstimulation syndrome: a prospective randomized trial.
    Gynecol Endocrinol. 2023;39:2269281.
    >> Share

    October 2023
  9. TAHARA N, Ito F, Kawamata M, Otani M, et al
    Dienogest does not augment the gene expression of adhesion molecules, MCP-1, and monocyte adherence in human endothelial cells.
    Gynecol Endocrinol. 2023;40:2270621.
    >> Share

    June 2023
  10. PINGARRON SANTOFIMIA C, Poyo Torcal S, Lopez Verdu H, Henriquez Linares A, et al
    Evaluation of the efficacy of an antioxidant combination for the modulation of metabolic, endocrine, and clinical parameters in patients with polycystic ovary syndrome.
    Gynecol Endocrinol. 2023;39:2227277.
    >> Share

    May 2023
  11. BOUNOUS VE, Actis S, Rosso R, Giorgi M, et al
    No-daily hormonal contraception today: general overview and application in specific clinical settings.
    Gynecol Endocrinol. 2023;39:2214626.
    >> Share

  12. JI L, Jin L, Shao MJ, Hu M, et al
    Levonorgestrel-releasing intrauterine system effects on metabolic variables in PCOS.
    Gynecol Endocrinol. 2023;39:2208667.
    >> Share

    March 2023
  13. NAPPI RE, Tiranini L, Bosoni D, Cucinella L, et al
    Women's attitudes about combined hormonal contraception (CHC) - induced menstrual bleeding changes - influence of personality traits in an Italian clinical sample.
    Gynecol Endocrinol. 2023 Mar 14:2189971. doi: 10.1080/09513590.2023.2189971.
    >> Share

    January 2023
  14. VON STOCKUM S, Becker K, Bauerfeind A, Franke C, et al
    NOMAC-E2 compares to LNG combined oral contraceptives in women over forty: real-world PRO-E2 study.
    Gynecol Endocrinol. 2023 Jan 23:1-5. doi: 10.1080/09513590.2023.2166032.
    >> Share

  15. VON STOCKUM S, Bauerfeind A, Becker K, Franke C, et al
    NOMAC-E2 shows a better contraceptive effectiveness than LNG combined oral contraceptives in women under 25: real-world PRO-E2 study.
    Gynecol Endocrinol. 2023 Jan 8:1-6. doi: 10.1080/09513590.2022.2162036.
    >> Share

    October 2022
  16. REGIDOR PA, Colli E
    The progestin-only pills drospirenone 4 mg and desogestrel 0.075 mg as an option for the management of dysmenorrhea and mastodynia.
    Gynecol Endocrinol. 2022 Oct 20:1-5. doi: 10.1080/09513590.2022.2134339.
    >> Share

    August 2022
  17. MIAO J, Lu J, Tang J, Lu P, et al
    Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
    Gynecol Endocrinol. 2022;38:656-660.
    >> Share

  18. MIN M, Ruan X, Wang H, Cheng J, et al
    Effect of orlistat during individualized comprehensive life-style intervention on visceral fat in overweight or obese PCOS patients.
    Gynecol Endocrinol. 2022;38:676-680.
    >> Share

    July 2022
  19. GU M, Ruan X, Li Y, Li T, et al
    Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat.
    Gynecol Endocrinol. 2022;38:598-602.
    >> Share

    June 2022
  20. OKYAY RE, Cetintas B, Akdoner A, Oztura I, et al
    The effect of oral contraceptive use on sympatic nerve activity in patients with polycystic ovary syndrome.
    Gynecol Endocrinol. 2022 Jun 7:1-6. doi: 10.1080/09513590.2022.2082403.
    >> Share

    May 2022
  21. LEPPANEN R, Tinkanen H, Huhtala H, Ahinko K, et al
    Single-administered GnRH agonist as luteal phase support in insemination cycles: a randomized controlled trial.
    Gynecol Endocrinol. 2022;38:438-442.
    >> Share

    April 2022
  22. REGIDOR PA, Palacios S, Colli E
    Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4 mg over nine cycles compared to desogestrel 0.075 mg.
    Gynecol Endocrinol. 2022;38:333-338.
    >> Share

    March 2022
  23. KIZILKAYA Y, Ibanoglu MC, Kiykac Altinbas S, Engin-Ustun Y, et al
    A prospective study examining the effect of dienogest treatment on endometrioma size and symptoms.
    Gynecol Endocrinol. 2022 Mar 23:1-4. doi: 10.1080/09513590.2022.2053956.
    >> Share

  24. VANNUCCINI S, Biagiotti C, Esposto MC, La Torre F, et al
    Long-term treatment of endometriosis-related pain among women seeking hormonal contraception.
    Gynecol Endocrinol. 2022 Mar 3:1-5. doi: 10.1080/09513590.2022.2047172.
    >> Share

    January 2022
  25. TRIGO ACM, Maron CC, Pinheiro MSA, da Silva SBL, et al
    Female sexual function in women using LARC methods.
    Gynecol Endocrinol. 2022;38:68-72.
    >> Share

    December 2021
  26. BUGGIO L, Barbara G, Facchin F, Ghezzi L, et al
    The influence of hormonal contraception on depression and female sexuality: a narrative review of the literature.
    Gynecol Endocrinol. 2021 Dec 16:1-9. doi: 10.1080/09513590.2021.2016693.
    >> Share

    November 2021
  27. JI M, Yuan M, Jiao X, Li Q, et al
    A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
    Gynecol Endocrinol. 2021 Nov 9:1-6. doi: 10.1080/09513590.2021.2000961.
    >> Share

    September 2021
  28. FERREIRA-FILHO ES, Bahamondes L, Duarte DC, Guimaraes ALM, et al
    Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report.
    Gynecol Endocrinol. 2021 Sep 6:1-4. doi: 10.1080/09513590.2021.1974380.
    >> Share

    August 2021
  29. REGIDOR PA, Colli E, Palacios S
    Overall and bleeding-related discontinuation rates of a new oral contraceptive containing 4 mg drospirenone only in a 24/4 regimen and comparison to 0.075 mg desogestrel.
    Gynecol Endocrinol. 2021 Aug 17:1-7. doi: 10.1080/09513590.2021.1963432.
    >> Share

  30. NIE L, Zou H, Ma X, Cheng L, et al
    A clinical observational study on the efficacy of subcutaneous etonogestrel implants for adenomyosis in 20 patients.
    Gynecol Endocrinol. 2021;37:735-739.
    >> Share

    June 2021
  31. YAO W, Dong X, Yu X, Luo J, et al
    The use of oral contraceptive is inversely associated with the risk of type 2 diabetes mellitus among middle-aged women.
    Gynecol Endocrinol. 2021 Jun 1:1-6. doi: 10.1080/09513590.2021.1932802.
    >> Share

    May 2021
  32. NICOLAS I, Martinez-Zamora MA, Gracia M, Carrion A, et al
    Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up.
    Gynecol Endocrinol. 2021 May 28:1-5. doi: 10.1080/09513590.2021.1929152.
    >> Share

  33. CECCARONI M, Clarizia R, Liverani S, Donati A, et al
    Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial.
    Gynecol Endocrinol. 2021 May 26:1-4. doi: 10.1080/09513590.2021.1929151.
    >> Share

  34. LI J, Sun Y, Mo S, Wang S, et al
    Effects of oral contraceptive for different responder women before GnRH antagonists: a systematic review and meta-analysis.
    Gynecol Endocrinol. 2021 May 11:1-10. doi: 10.1080/09513590.2021.1918664.
    >> Share

    March 2021
  35. MARIANI LL, Novara L, Mancarella M, Fuso L, et al
    Estradiol/nomegestrol acetate as a first-line and rescue therapy for the treatment of ovarian and deep infiltrating endometriosis.
    Gynecol Endocrinol. 2021 Mar 22:1-4. doi: 10.1080/09513590.2021.1903420.
    >> Share

  36. PIACENTI I, Viscardi MF, Masciullo L, Sangiuliano C, et al
    Dienogest versus continuous oral levonorgestrel/EE in patients with endometriosis: what's the best choice?
    Gynecol Endocrinol. 2021 Mar 2:1-5. doi: 10.1080/09513590.2021.1892632.
    >> Share

  37. TROIA L, Martone S, Morgante G, Luisi S, et al
    Management of perimenopause disorders: hormonal treatment.
    Gynecol Endocrinol. 2021;37:195-200.
    >> Share

    February 2021
  38. BUYUK GN, Oskovi-Kaplan ZA, Kansu-Celik H, Neselioglu S, et al
    Copper and levonorgestrel containing intrauterine devices: comparison of their effect on oxidative stress markers.
    Gynecol Endocrinol. 2021 Feb 17:1-4. doi: 10.1080/09513590.2021.1878132.
    >> Share

  39. CLEMENZA S, Vannuccini S, Capezzuoli T, Meleca CI, et al
    Is primary dysmenorrhea a precursor of future endometriosis development?
    Gynecol Endocrinol. 2021 Feb 11:1-7. doi: 10.1080/09513590.2021.1878134.
    >> Share

    January 2021
  40. ATAKUL T, Tayyar AT, Turan OD, Celik SY, et al
    An assessment of the protective effect of gonadotropin-releasing hormone agonist and antagonist on bleomycin-induced ovarian toxicity in rats.
    Gynecol Endocrinol. 2021;37:46-50.
    >> Share

    October 2020
  41. LI X, Zhang X, Cai J, Pang J, et al
    Granulosa cells apoptosis and follicular fluid hormones: comparison of progestin-primed ovarian stimulation versus GnRH antagonist protocols.
    Gynecol Endocrinol. 2020 Oct 23:1-5. doi: 10.1080/09513590.2020.1822802.
    >> Share

    June 2020
  42. STEFANIAK A, Domitrz J, Siewko K, Szelachowska M, et al
    Pituitary adenoma and apoplexy during GnRH agonist treatment for IVF - case report.
    Gynecol Endocrinol. 2020;36:561-563.
    >> Share

    May 2020
  43. DEL FORNO S, Degli Esposti E, Salucci P, Leonardi D, et al
    Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience.
    Gynecol Endocrinol. 2020;36:445-447.
    >> Share

    April 2020
  44. LASORELLA S, Porto R, Iezzi ML, Pistone C, et al
    Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study.
    Gynecol Endocrinol. 2020;36:338-340.
    >> Share

    February 2020
  45. VIGNALI M, Belloni GM, Pietropaolo G, Barbasetti Di Prun A, et al
    Effect of Dienogest therapy on the size of the endometrioma.
    Gynecol Endocrinol. 2020 Feb 16:1-5. doi: 10.1080/09513590.2020.1725965.
    >> Share

    December 2019
  46. PALAIA I, Del Negro V, Fracassi A, Schiavi M, et al
    Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.
    Gynecol Endocrinol. 2019 Dec 26:1-2. doi: 10.1080/09513590.2019.1707795.
    >> Share

  47. XHOLLI A, Filip G, Previtera F, Cagnacci A, et al
    Modification of endometrioma size during hormone therapy containing dienogest.
    Gynecol Endocrinol. 2019 Dec 16:1-5. doi: 10.1080/09513590.2019.1703942.
    >> Share

    October 2019
  48. MATSUSHIMA T, Akira S, Yoneyama K, Takeshita T, et al
    Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest.
    Gynecol Endocrinol. 2019 Oct 29:1-4. doi: 10.1080/09513590.2019.1683818.
    >> Share

    August 2019
  49. PALAIA I, Bardhi E, Boccia SM, Pecorini F, et al
    Severe hemoperitoneum due to endometriosis in a non-pregnant woman under dienogest therapy: a case report.
    Gynecol Endocrinol. 2019 Aug 13:1-2. doi: 10.1080/09513590.2019.1653843.
    >> Share

  50. GIARRE G, Franchini M, Castellacci E, Malune ME, et al
    Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study.
    Gynecol Endocrinol. 2019 Aug 8:1-4. doi: 10.1080/09513590.2019.1648419.
    >> Share

    July 2019
  51. BISCIONE A, Barra V, Bellone E, Severi FM, et al
    Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis.
    Gynecol Endocrinol. 2019 Jul 22:1-6. doi: 10.1080/09513590.2019.1640202.
    >> Share

  52. ANGIONI S, Pontis A, Malune ME, Cela V, et al
    Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study.
    Gynecol Endocrinol. 2019 Jul 16:1-3. doi: 10.1080/09513590.2019.1640674.
    >> Share

  53. MUZII L, Galati G, Di Tucci C, Di Feliciantonio M, et al
    Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain.
    Gynecol Endocrinol. 2019 Jul 14:1-3. doi: 10.1080/09513590.2019.1640199.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016